Shots:
- Monte Rosa has collaborated with Novartis to develop novel degraders for immune-mediated diseases, leveraging Monte Rosa’s QuEEN discovery engine
- As per the deal, Novartis will gain an exclusive license to an undisclosed discovery target & options to license 2 programs from Monte Rosa’s preclinical immunology portfolio
- The deal is valued at ~$5.7B, with Monte Rosa receiving $120M upfront, option maintenance fees, preclinical milestone, option exercise & development, regulatory & sales milestone payments across programs, with tiered net-sales royalties ranging from high single to low double digits
Ref: Monte Rosa | Image: Monte Rosa & Novartis | Press Release
Related News:- Argo Biopharma Inks a ~$5.3B Deal with Novartis for Multiple Cardiovascular Assets, Expanding their Existing Partnership
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
